secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xenetic Biosciences, Inc. (XBIO)
CIK:        0001534525
Form:       8-K
Filed at:   2021-08-13T23:59:59+00:00
Accession:  0001683168-21-003522
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xenetic Biosciences reports Q2 2021 net loss of $1.1M; completes $12.5M private placement
--------------------------------------------------------------------------------

- Net loss $1.1M for Q2 2021; cash $9.3M at quarter end.
- R&D expenses rose 70.4% to $0.5M, driven by XCART spending.
- Received ~$0.3M in royalty payments from Takeda sublicense in Q2.
- Completed $12.5M private placement in August 2021, net proceeds ~$11.4M.
- Advancing XCART personalized CAR T platform toward IND-enabling studies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534525/000168316821003522/0001683168-21-003522-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534525/000168316821003522/xenetic_i8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-21-003522

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer